Digoxin: Cardiac Glycoside for Heart Failure and Antiviral Research

Executive Summary: Digoxin is a high-purity cardiac glycoside and potent Na+/K+-ATPase pump inhibitor (APExBIO, Digoxin), widely used to enhance cardiac contractility in heart failure research and to inhibit arrhythmias [DOI]. It demonstrates dose-dependent antiviral activity against chikungunya virus (CHIKV) in multiple human cell lines. Digoxin is soluble in DMSO at ≥33.25 mg/mL but is insoluble in water and ethanol. Preclinical animal models confirm its efficacy in improving cardiac output and reducing right atrial pressure. APExBIO’s Digoxin (SKU: B7684) is supplied at high purity and accompanied by comprehensive quality control documentation [APExBIO Product Page].

Biological Rationale

Digoxin is a canonical cardiac glycoside derived from Digitalis species. It is extensively utilized to probe the physiological and pathological mechanisms of cardiac contractility, arrhythmia, and heart failure in research contexts [Digoxin: Cardiac Glycoside for Heart Failure Research]. Its primary target, the Na+/K+-ATPase pump, is crucial for maintaining electrochemical gradients across cardiomyocyte membranes. Inhibition of this pump by Digoxin increases intracellular sodium, which indirectly elevates intracellular calcium via the Na+/Ca2+ exchanger. This leads to enhanced force of contraction (positive inotropy). Beyond cardiovascular research, Digoxin has demonstrated antiviral properties, particularly against chikungunya virus (CHIKV) in human and primate cell lines. The compound’s dual action enables researchers to study both cardiac and viral pathophysiology with a single agent.

Mechanism of Action of Digoxin

Digoxin inhibits the Na+/K+-ATPase pump found on the plasma membrane of cardiomyocytes and other cells. This inhibition disrupts the active transport of sodium and potassium ions, leading to increased intracellular sodium concentrations. Elevated sodium levels reduce the activity of the Na+/Ca2+ exchanger, resulting in higher intracellular calcium. Increased calcium availability enhances myocardial contractility and supports anti-arrhythmic effects in heart failure models [Cardiac Glycoside and Na+/K+ ATPase Pump Inhibitor]. In virology research, Digoxin impairs CHIKV infection by interfering with viral entry and replication mechanisms in a dose-dependent manner (0.01–10 μM), as confirmed in U-2 OS, primary human synovial fibroblasts, and Vero cell assays [DOI].

Evidence & Benchmarks

• Digoxin (SKU: B7684) inhibits Na+/K+-ATPase pump activity in mammalian cardiomyocytes, leading to increased intracellular sodium and calcium concentrations, enhancing contractility (APExBIO, product page).
• In vitro studies show Digoxin blocks CHIKV infection in human U-2 OS, primary synovial fibroblast, and Vero cells in a dose-dependent manner at 0.01–10 μM (Sun et al., DOI:10.1016/j.biopha.2025.118665).
• Digoxin is insoluble in water and ethanol, but dissolves at ≥33.25 mg/mL in DMSO at 20–25°C (APExBIO, product documentation).
• Animal models (canine, intravenous Digoxin 1–1.2 mg) demonstrate improved cardiac output and reduced right atrial pressure in congestive heart failure (CHF) (APExBIO, product page).
• Digoxin is provided at >98.6% purity, validated by HPLC, NMR, and MSDS (APExBIO, product specs).
• Pharmacokinetic variability in related alkaloids (e.g., berberine) is modulated by disease state and transporter expression, suggesting the importance of standardized dosing (Sun et al., DOI).

This article extends the data-driven guidance in "Digoxin (SKU B7684): Data-Driven Solutions for Cell and Cardiac Assays" by integrating up-to-date antiviral benchmarks and highlighting PK variability considerations for complex disease models.

Applications, Limits & Misconceptions

Digoxin is widely applied in research models of heart failure, arrhythmias, and more recently, viral pathogenesis. Its high specificity for the Na+/K+-ATPase pump allows for targeted manipulation of cardiac and cellular signaling pathways. In virology, Digoxin’s ability to inhibit CHIKV has been mechanistically validated in human cell models.

Common Pitfalls or Misconceptions

• Digoxin is not water-soluble or ethanol-soluble; improper solvent selection can lead to precipitation and loss of activity.
• It is not suitable for long-term storage in solution; freshly prepared DMSO solutions are recommended for experimental use (room temperature, use within hours).
• Digoxin is not a general antiviral; its activity has been documented against CHIKV, but may not extend to unrelated viral families.
• Not intended for clinical therapy or human administration; for research use only.
• Cardiotoxicity can occur at supra-physiological doses; experimental concentrations should be carefully titrated and monitored.

This article clarifies misconceptions addressed in "Digoxin: Cardiac Glycoside and Na+/K+ ATPase Pump Inhibitor" by specifying solubility constraints and non-clinical use.

Workflow Integration & Parameters

APExBIO’s Digoxin (SKU: B7684) is supplied as a solid and should be stored at room temperature in a desiccated environment. For in vitro use, dissolve Digoxin in DMSO at concentrations ≥33.25 mg/mL. Prepare working solutions immediately prior to use; avoid freezing or long-term storage of reconstituted product. Standard experimental concentrations for antiviral assays are 0.01–10 μM, with cytotoxicity and antiviral endpoints validated in U-2 OS and Vero cell systems. In animal models, dosing regimens (e.g., 1–1.2 mg IV in canine CHF) should be referenced from published protocols and titrated based on species and experimental design.

For broader context, see "Digoxin Redefined: Strategic Deployment of a Cardiac Glycoside", which discusses the translational relevance and PK nuances in MASLD/MASH models—this article provides additional procedural detail and practical limits for cell and animal workflows.

Conclusion & Outlook

Digoxin remains a cornerstone tool in both cardiovascular and antiviral research. Its well-characterized mechanism of action and validated experimental benchmarks support its use in reproducible, mechanistically rigorous studies. Ongoing research is expanding its utility in translational models of infection and metabolic disease. APExBIO’s high-purity Digoxin (SKU: B7684) provides researchers with a robust, reliable reagent for next-generation discovery. For specifications and documentation, refer to the APExBIO product page.